Research programme: Herpes simplex virus nanoparticle therapies - NanoViricides
Alternative Names: Herpicide™; Herpicide™-ILatest Information Update: 28 Mar 2025
At a glance
- Originator TheraCour Pharma
- Developer NanoViricides
- Class Antivirals; Polymers
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dendritic keratitis; Herpes labialis; Herpes simplex virus infections; Herpes zoster
- No development reported Retinal disorders
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Dendritic-keratitis in USA (Ophthalmic, Gel)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (SC)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Intravitreous, Injection)